Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
STOCKHOLM, April 26, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme").
For this purpose, Sobi has prepared a base prospectus, which has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The base prospectus will be made available on Sobi's website.
SEB has been appointed arranger of the MTN Programme and will also act as dealer together with Danske Bank, Nordea and Svenska Handelsbanken. Mannheimer Swartling acted as legal adviser to Sobi.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
bluebird bio, Inc. announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.
To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and...
RSA CONFERENCE ? As a new crop of AI-related threats emerges from the rapid adoption of generative AI (GenAI) tools within application development, Checkmarx, the industry leader in cloud-native application security for the enterprise, has forged a...
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the European Patent Office for its...
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and...
Today, Ticura emerges from stealth, unveiling a groundbreaking solution that is set to redefine the cyber threat intelligence landscape, and empower security solution providers to tailor their threat prevention and detection offerings for individual...